Skip to main content

Table 2 PET/CT analysis: interobserver agreement (N = 9 studies)

From: 18F- FDG PET/CT joint assessment of early therapeutic response in rheumatoid arthritis patients treated with rituximab

Joints

Baseline

W16

Visual analysis

SUVs

Visual analysis

SUVs

Kappa (CI 95%)

CCC (CI 95%)

Kappa (CI 95%)

CCC (CI 95%)

Knees

0.75 (0.42, 1.00)

0.95 (0.86, 0.98)

0.85 (0.57, 1.00)

0.92 (0.80, 0.97)

Wrists

0.73 (0.38, 1.00)

0.80 (0.71, 0.86)

0.75 (0.44, 1.00)

0.93 (0.90, 0.96)

MCPs

0.77 (0.63, 0.90)

0.97 (0.96, 0.98)

0.69 (0.54, 0.84)

0.86 (0.80, 0.91)

PIPs

0.80 (0.67, 0.92)

0.99 (0.96, 1.00)

0.64 (0.49, 0.81)

0.97 (0.91, 0.99)

Global

0.79 (0.70, 0.87)

0.93 (0.61, 0.94)

0.70 (0.61, 0.80)

0.93 (0.91, 0.95)